Advancing Cancer Treatment with CureVac Proprietary mRNA Technology
Broadly, we aim to develop off-the-shelf cancer vaccines across different indications that share common tumor-specific antigens, explains Alexander Zehnder, CEO, CureVac in an engaging session with Aishwarya Saxena, Pharma Industrial India.
MRNA Drugs | 14/05/2024
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy